Asset Details
Do you wish to reserve the book?
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Do you wish to request the book?
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
2022
Overview
In this randomized noninferiority trial involving patients with rheumatoid arthritis, cardiovascular events and cancers occurred more frequently with tofacitinib than with a TNF inhibitor, and noninferiority of tofacitinib with respect to these end points was not established.
Publisher
Massachusetts Medical Society
Subject
/ Antirheumatic Agents - adverse effects
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Rheumatoid - drug therapy
/ Cardiovascular Diseases - chemically induced
/ Cardiovascular Diseases - epidemiology
/ Female
/ Humans
/ Janus Kinase Inhibitors - administration & dosage
/ Janus Kinase Inhibitors - adverse effects
/ Janus Kinase Inhibitors - therapeutic use
/ Male
/ Neoplasms - chemically induced
/ Oncology
/ Patients
/ Piperidines - administration & dosage
/ Piperidines - adverse effects
/ Piperidines - therapeutic use
/ Pyrimidines - administration & dosage
/ Pyrimidines - adverse effects
